Ah—where are you seeing that? The endTB page mentions under “What’s next?” the phase III endTB-Q trial, but that’s for pre-XDR TB, with “results [...] expected in late 2024″.
You’re right, I picked up the endTB-Q trial expected to announce findings in 2025, but missed that endTB-Q had a different target (fluoroquinolone-resistant MDR-TB) and wasn’t just a continuation of the previous tests with a different drug cocktail.
Ah—where are you seeing that? The endTB page mentions under “What’s next?” the phase III endTB-Q trial, but that’s for pre-XDR TB, with “results [...] expected in late 2024″.
You’re right, I picked up the endTB-Q trial expected to announce findings in 2025, but missed that endTB-Q had a different target (fluoroquinolone-resistant MDR-TB) and wasn’t just a continuation of the previous tests with a different drug cocktail.